Showing results (211-220 of 370) with videos related to

Sort By:
Pageof 37
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2022
An uncharacteristically low-potential flavin governs the energy landscape of electron bifurcationCourtney E Wise, Anastasia E Ledinina, David W Mulder, et al.
Iscience|November 23, 2018
Single-Cell ID-seq Reveals Dynamic BMP Pathway Activation Upstream of the MAF/MAFB-Program in Epidermal DifferentiationRoderick A P M van Eijl, Jessie A G L van Buggenum, Sabine E J Tanis, et al.
Pharmacological Research|September 5, 2002
Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individualsC H W Koks, K M L Crommentuyn, R A A Mathôt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2004
Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosisKristel M L Crommentuyn, Jan W Mulder, Rolf W Sparidans, et al.
Clinical Pharmacokinetics|July 21, 2005
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individualsBregt S Kappelhoff, Alwin D R Huitema, Zeynep Yalvaç, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|June 1, 1997
Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patientsR M Hoetelmans, C L Kraaijeveld, P L Meenhorst, et al.
The Journal of Infectious Diseases|September 1, 1993
Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudineM Koot, P T Schellekens, J W Mulder, et al.
Pageof 37